OPEN ACCESS **molecules** ISSN 1420-3049 www.mdpi.com/journal/molecules

Communication

Frameshifting in the P6 cDNA Phage Display System

Cindy Govarts, Klaartje Somers, Piet Stinissen and Veerle Somers *

Biomedical Research Institute, School of Life Sciences, Transnationale Universiteit Limburg and Hasselt University, Diepenbeek, Belgium

* Author to whom correspondence should be addressed; E-Mail: veerle.somers@uhasselt.be; Tel.: +32-11-269-202; Fax: +32-11-269-299.

Received: 9 *November 2010; in revised form: 3 December 2010 / Accepted: 16 December 2010 / Published: 20 December 2010*

Abstract: Phage display is a powerful technique that enables easy identification of targets for any type of ligand. Targets are displayed at the phage surface as a fusion protein to one of the phage coat proteins. By means of a repeated process of affinity selection on a ligand, specific enrichment of displayed targets will occur. In our studies using C-terminal display of cDNA fragments to phage coat protein p6, we noticed the occasional enrichment of targets that do not contain an open reading frame. This event has previously been described in other phage display studies using N-terminal display of targets to phage coat proteins and was due to uncommon translational events like frameshifting. The aim of this study was to examine if C-terminal display of targets to p6 is also subjected to frameshifting. To this end, an enriched target not containing an open reading frame was selected and an E-tag was coupled at the C-terminus in order to measure target display at the surface of the phage. The tagged construct was subsequently expressed in 3 different reading frames and display of both target and E-tag measured to detect the occurrence of frameshifting. As a result, we were able to demonstrate display of the target both in the 0 and in the +1 reading frame indicating that frameshifting can also take place when C-terminal fusion to minor coat protein p6 is applied.

Keywords: cDNA phage display; E. coli; frameshifting; p6; filamentous phage

1. Introduction

Phage display is a high-throughput molecular technique that has been used successfully to select targets for any given ligand. Targets can be easily displayed on the surface of the phage virion by coupling the foreign DNA to a gene encoding a phage coat protein. After infection of the host, phage protein components are produced by the protein translation machinery of the infected bacterial cell and the foreign DNA will be displayed as a fusion product to one of the phage coat proteins [1]. Because of the physical link between genotype and phenotype, filamentous phage displaying a relevant polypeptide will be retained during affinity selections on candidate binding ligands followed by identification of the target [2].

The most commonly used phage coat proteins for fusion are minor coat protein 3 (p3) and major coat protein 8 (p8) [3,4]. When using these coat proteins, N-terminal fusion of the target is mandatory for successful phage propagation. For the display of cDNA libraries, N-terminal fusion is not possible due to inherent stop codons present in the cDNA fragments, as represented in Figure 1. However, the free carboxyl terminus of minor coat protein 6 (p6) allows successful fusion of the cDNA without interfering with phage propagation [5]. Using the pSP6 phagemid vector which was specifically designed to enable C-terminal fusion of targets to p6, we and others have already successfully identified a variety of targets [5-11].




Figure 1. N- and C-terminal fusion of cDNA to a phage coat protein.

In our previous studies using C-terminal fusion of cDNA to p6, we observed that during affinity selections a small percentage of phages containing a stop codon immediately after gene VI (gVI) became enriched. This stop codon resulted from an out of frame insertion of the cDNA into the phagemid vector thereby preventing the display of the corresponding protein. Although we initially thought that the isolation of these clones could be the result of aspecific binding, the enrichment of identical cDNA sequences containing this stop codon suggested specific interactions of a displayed target with a ligand. This display could occur when unusual translational recoding such as frameshifting or ribosome hops take place.

Frameshifting is well established within the field of phage display and bacterial expression systems [12-16]. Because previous studies were based on N-terminal fusion to p3 or p8, frameshifting had to occur in order to express the p3 and p8 coat proteins that enable phage propagation. However, C-terminal fusion to p6 does not require expression of the inserted cDNA for successful phage propagation as represented in figure 1 [5,6]. Therefore, other methods must be used to detect the possible occurrence of these unusual translational events.

In the work described here, a phage clone UH-FS was chosen for further study of frameshifting in the p6 display system. UH-FS was previously isolated after affinity selecting a multiple sclerosis (MS) cDNA display library against antibodies present in MS sera [10]. Although the inserted cDNA sequence of the phage clone encodes part of the Apolipoprotein E protein (ApoE), out of frame insertion of the cDNA sequence into the pSP6 phagemid vector resulted in an early stop codon thereby preventing the display of the protein. Fusion of an E-tag to the ApoE cDNA and subcloning of the fragment in 3 reading frames in the pSP6 vector resulted in the expression of the ApoE - E-tag construct in all reading frames. Measuring expression of both the ApoE polypeptide and the E-tag via ELISA revealed an increased expression both in the correct reading frame but also in the +1 reading frame, indicating the occurrence of frameshifting in the p6 display system. In addition we could demonstrate an increased antibody reactivity towards the correctly displayed ApoE polypeptide in the plasma of the MS patients used for the selection rounds, which strongly indicates the specific enrichment of UH-FS. An overview of the study is represented in figure 2.

2. Results and Discussion

2.1. Fusion of an E-tag to the ApoE cDNA Sequence

The inserted cDNA sequence of UH-FS encoded part of the signal sequence in addition to the first 130 amino acids (AA) of the ApoE protein. However, due to out of frame insertion of the ApoE gene in the pSP6 phagemid vector, a stop codon was observed immediately after gVI that prevented the display of the corresponding ApoE polypeptide. In order to detect whether this clone could be subjected to frameshifting, an E-tag was cloned in frame at the 3'-end of the ApoE cDNA as depicted in Figure 2A in order to obtain simultaneous expression of the ApoE polypeptide and the E-tag. This ApoE - E-tag construct was then subcloned into the pSP6 vector in 3 different reading frames (Figure 2E). This resulted in the insertion of the ApoE - E-tag in the 0 frame (designated UH-FSE⁻¹, Figure 3B) where a stop codon prevents the display of a peptide and the +1 frame (designated UH-FSE⁺¹, Figure 3C) in which an artificial peptide of 17 AA is displayed at the surface of the phage. As a control for E-tag expression, the E-tag alone was inserted in the pSP6 vector in the 0 frame (designated UH-PC) and in the -1 frame (designated UH-NC) resulting in respectively high and no E-tag expression (Figure 2B).

Figure 2. Overview of the study. First the E-tag (red) was coupled to the 3' site of the ApoE sequence (grey) (**A**) and E-tag display controls were made (**B**). After cloning the constructs into the pCR2.1 TOPO vector and pSP6 vectors (**C-D**), different phages were purified (**E**). Phage UH-FSE⁰ correctly displays the ApoE polypeptide (grey) and E-tag (red) fused to p6 (blue) (**E1**). UH-FSE⁻¹ (**E2**) and UH-FSE⁺¹ (**E3**) express the ApoE construct with, respectively, a -1 and +1 shift in the reading frame. Although these phages normally do not express the ApoE polypeptide, part of them will if frameshifting would occur. A positive (**E4**) and negative (**E5**) E-tag display control was also purified. Expression of both ApoE polypeptide and E-tag were subsequently measured by ELISA (**F**).

A) Addition of an E-tag and NotI restriction site 3' of the ApoE sequence





Figure 3. (a) ApoE in UH-FSE⁻¹; (b) UH-FSE⁰ and (c) UH-FSE⁺¹.




| ATE CCA GTT CTT TTE GTT ATT TAT TTE GAT TGE GAT TAA GGA TCC GGT GGA GGC TCA GGC GG M P V L L V I Y L D W D K G S G S G S G S G Q V G Q I F Q R I R H E G E G R P S P G A GA CTE GC CAG GAC GAG GAT GA GA CTT C CCA GA GAC GAC GAG GAT GA AS GTT CT GTG GC TTE CTG TG GC TTE CTG TTE CTT TTE GTT ATT TAT TTE GAT TGE GC TG CTG CTT CTC CC AGG AGT ATT A P V L L V I Y L D W D X G S G G G S G T TA TT T L D V L L V I Y L D W D X G S C TTE CTC TTE CTC AGA AGT GA GC TTE TTE GC TTE CTG TG GC TG GC TG GC TTE CTC CA AGT AGT AGA GC TTE GC GC TG GC TTE CTC CTA GG AGT CA AGT GA GC TTE GC GC TG GC TG GC TG GC GC GT GC GC TTE CTC GC AGT CT C CTC AGA AGT GA GC TTE GC GC TG GC TG GC TG GC GC GC GC TAA TTA TT T G TT TTE GTT ATT TAT TTE GAT TGE GC TG CT GC GC GC GT GC GC GT GC GC GC TAA TTA TT G TT CTG GC A GC TG GC GC GC GC GC TAA TTA ATT G TT CTG GC AGT CAC AGG GT GC GC GC GC TAA TTA ATT G TT GC GC AGT CCC GC GC TG GC CG TTA TTA TTO GC TG GC AGT CCC GC AGA CTC CCC GC GC GC TAA TTA TT G TT G | | - | | | | | | Geı | ne VI | 7 Linker | | |
|--|----------|---|--|--|---|---|---|---|-------------------------------------|--|--|--|
| $ \begin{array}{c} \mathbf{E} \operatorname{corr} \mathbf{F} \operatorname{corr} co$ | | ATG | CCA | GTT | CTT | TTG | GTT | ATT | | TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC G | | |
| GGC CAA GTC GGC CAG ATC TTC TAG AGA AGA CAT CAG GAG GAT GAA GGA CGT CCT TCC CCA GGA GGC G Q V G Q I F Q R I R H E G E G R P S P G A GAC TGG CCA ATC ACA GGC AGG AAG AAG AAG AAG ATC TC TG TGG GCG TG CTG GTC ACA TTC | | М | P | v | L | L | v | I | | Y L D W D K G S G G S G (| | |
| GGC CRA GTC GGC CAG ATC TTC TAG AGA TC CGC CGC GAG GGT GAA GGA CGT CCT TCC CCA GGA GGC G Q V G Q I F Q R I R H E G E G R P S P G A GAC TGG CCA ATC ACA GGC AGG AAG ATG AAG GTT CTG TGG GCC GGT GCC GT CCT CCC CAG GA GCC D W P I T G R K M K V L W A A L L V T F | | | | | | | | | | E DI ANGE (DNA | | |
| G Q V G Q I F Q R I R H E G E G R P S P G A GAC TGG CCA ATC ACA GGC AGG AGA ATG AAG GTT CTG TGG GCT GCG TGG CTG GTA CATTC D W P I T G R K M K V L W A A L L V T F GCG GCG CAG GCC CGG CTG GGC GGC GAC ATG GAG GGC GTG TGC GGT GCG CTG GTA TT CGG GAT A A Q A R L G A D M E D V C G A P V P Y P D C G C TG GAA CC CGT <u>GCG GCC GT</u> AAT TAA P L E P R A A A N * D'UHFNE ⁻¹ : no peptide displayed at the sufface of the phage \longrightarrow T T TG GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGG GGC GGG GGG GGG GGG GGG GGG | | GGC | CAA | GTC | GGC | CAG | ATC | TTC | TAG | | | |
| GAC TGG CCA ATC ACA GGC AGG AGG AGG ATG AAG GTT CTG TGG GCT GCG TTG CTG GCC ACT TC D W P I T G R K M K V L W A A L L V T P GCG GCG CAG GCC CGG CTG GGC GCG ATG GAA GAC GG GTG CGG CGG GTG CGG TAT CGG GAT A A Q A R L G A D M E D V C G A P V P Y P D CGG CTG GAA CGC CGG GCG GCG T AAT TAA P L B P R A A A N * D UH-FSE ⁻¹ : no peptide displayed at the surface of the phage | | | | | | | | | | | | |
| D W P I T G R K M K V L W A A L L V T P GCG GCG CAG GCC CGG CTG GGG GCG GAC ATG GAG GAC GTG TGC GGT GGC CG GTAT CCG GAT A A Q A R L G A D M E D V C G A P V P Y P D CCG CTG GAA CCG CGT <u>GCG GCC GC</u> AAT TAA P L E P R A A A N * D UH-FSE ⁻¹ : no peptide displayed at the surface of the phage $\begin{array}{c} \hline & & & & \\ \hline & & & & \\ \hline & & & & \\ \hline & & & &$ | | | ~ | | | ~ | | | ~ | | | |
| D W P I T G R K M K V L W A A L L V T P GCG GCG CAG GCC CGG CTG GGG GCG GAC ATG GAG GAC GTG TGC GGT GGC CG GTAT CCG GAT A A Q A R L G A D M E D V C G A P V P Y P D CCG CTG GAA CCG CGT <u>GCG GCC GC</u> AAT TAA P L E P R A A A N * D UH-FSE ⁻¹ : no peptide displayed at the surface of the phage $\begin{array}{c} \hline & & & & \\ \hline & & & & \\ \hline & & & & \\ \hline & & & &$ | | GAC | TGG | CCA | ATC | ACA | GGC | AGG | AAG | G ATG AAG GTT CTG TGG GCT GCG TTG CTG GTC ACA TTC | | |
| GCG GCG CAG GCC CGG CGG GCG GCG AAT GAG GAG GAG GGG GCG GCG GCG GCG GCG GCG | | D | W | Ρ | I | Т | G | R | Κ | M K V L W A A L L V T F | | |
| A A Q A R L G A D M E D V C G A P V P Y P D CG CTG GAA CGC GCT <u>GCG GCC GCT</u> AAT TAA P L E P R <u>A A A N</u> * UH-FSE⁻¹ no peptide displayed at the surface of the phage ATG CCA GTT CTT TTG GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC G M P V L L V I Y L D W D K G S G G G S G GG CCA AGT CGG CCA GAT CTT CTA GAG AAT TCG GCA CGA GG TGA AGG ACG TCC TCC CCA GGA AGG GG P S R P D L L E N S A R G * CGA CTG GCC AAT CAC AGG CAG GAA GAT GA AGG TCT GTG GGC TGC GTT GCT GGT CAC ATT C | | | | | 12012120 | | 1212210 | | | na manananan kuta bananan mananan mananan kutalara mananar manan selihin ^a ki s hari sebanan mananan marina sa | | |
| $\begin{array}{c} \hline \mathbf{E} \cdot \mathbf{fag} \longrightarrow \mathbf{Noll} \\ \hline \mathbf{Cos} \ \mathbf{Crs} \ \mathbf{Gaa} \ \mathbf{Ccs} \ \mathbf{Ccs} \ \mathbf{Gcs} \ $ | | | | | | | | | | | | |
| CCC CTG GAA CCG CCT <u>GCG GCC GCT</u> AAT TAA P L <u>B</u> P R A A A A N * UH-FSE ⁻¹ : no peptide displayed at the surface of the phage \overbrace{M} P V <u>L</u> <u>L</u> V <u>I</u> $$ <u>T</u> AT T = - TAT TTG GAT TGG GAT AAA GGA TCC GET GGA GGC TCA GGC C <u>M</u> P V <u>L</u> <u>L</u> V <u>I</u> <u>Y</u> <u>L</u> <u>D</u> W <u>D</u> <u>X</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>G</u> <u>S</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>G</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> <u>S</u> <u>G</u> <u>C</u> <u>G</u> <u>G</u> <u>S</u> <u>S</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>S</u> <u>G</u> <u>G</u> <u>S</u> <u>S</u> <u>S</u> <u>G</u> <u>C</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> <u>S</u> <u>S</u> <u>S</u> <u>G</u> <u>S</u> | | A | | | | | | | A | DMLDVCGAFVFIFD | | |
| UH-FSE ⁻¹ : no peptide displayed at the surface of the phage $M \ P \ V \ L \ L \ V \ I \ Y \ L \ D \ W \ D \ K \ G \ S \ G \ G \ S \ G \ G \ S \ G \ G$ | | CCG | | | · | CGT | GCG | GCC | GCT | Г ААТ ТАА | | |
| $\begin{array}{c} \textbf{Gene VI} \qquad \textbf{Gene VI} \qquad \textbf{Gene VI} \qquad \textbf{Formula} Finder in the property of the transformation of the property of transformation of the property of the transformation of transformation of the property of transformation of the property of transformation of tra$ | | Р | L | Е | P | R | A | A | A | N * | | |
| $\begin{array}{c} \textbf{C} \textbf{C} \textbf{C} \textbf{C} \textbf{C} \textbf{C} \textbf{C} C$ | 1 | THT | TOT | - 1 | | | : 1 | | | | | |
| ATG CCA GTT CTT TTG GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC CA GGC CGC C | <u> </u> | UH-FSE ⁻¹ : no peptide displayed at the surface of the phage | | | | | | | | | | |
| M P V L L V I Y L D W D K G S G G G S G EcoRI GGG CCA AGT CGG CGG GAT CTT CTA GAG AAT TCG GGC CGA GGG TGA AGG ACG TCC TTC CCC AGG AGG G P S R P D L L E N S A R G * CGA CTG GCC AAT CAC AGG CAG GAA GAT GAA GGT TCT GTG GGC TGC GTT GCT GGT CAC ATT C GGC GGC GCA GGC CGG GCT GGG CGC GAA GAT GAA GGT TCT GTG GGC TGC GTT GCT GGT CAC ATT C GGC GGC GCA GGC CGG GCT GGG CGC GGA CAT GGA GGA CGT GTG CGG TGC GGT GCC GTT TCC GGA TCC GCT GGA ACC GCG T <u>GC GGC CGC</u> TAA TTA ATT G UH-FSE ⁺¹ : display of an artificial peptide $\begin{array}{c} \hline \\ \hline \\ \hline \\ \\ \hline \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $ | | - | | | | | | | | - | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | | | | | | | - | | | |
| GGG CCA AGT CGG CCA GAT CTT CTA GAG <u>AAT</u> <u>TCG</u> GCA CGA GGG TGA AGG ACG TCC TTC CCC AGG AGG G P S R P D L L E N S A R G * CGA CTG GCC AAT CAC AGG CAG GAA GAT GAA GGT TCT GTG GGC TGC GCT GGT CAC ATT C GGC GGC GCA GGC CCG GCT GGG CGC GGA CAT GGA GGA CGT GTG CGG TGC GCC GTT TCC GGA TCC GCT GGA ACC GCG T <u>GC GGC CGC</u> TAA TTA ATT G UH-FSE ⁺¹ : display of an artificial peptide GGC GCC GCT GTG GTG GTG GTG GGC GGC TAA TTA ATT G UH-FSE+1: display of an artificial peptide $ GGC GCC GCT GTG GTG GTG GTG GGC GGC GGC$ | | М | P | v | L | L | v | I | | Y L D W D K G S G G S G | | |
| GGG CCA AGT CGG CCA GAT CTT CTA GAG <u>AAT</u> <u>TC</u> G GCA CGA GGG TGA AGG ACG TCC TTC CCC AGG AGG G P S R P D L L E N S A R G * CGA CTG GCC AAT CAC AGG CAG GAA GAT GAA GGT TCT GTG GGC TGC GCT GGT CAC ATT C GGC GGC GCA GGC CCG GCT GGG CGC GGA CAT GGA GGA CGT GTG CGG TGC GCC GTT TCC GGA TCC GCT GGA ACC GCG T <u>GC GGC CGC</u> TAA TTA ATT G UHI-FSE ⁺¹ : display of an artificial peptide GGC GGC GGC AGG CGC GGC GGC GGC GGC TAA TTA ATT G UHI-FSE+1: display of an artificial peptide $ GGC GGC GGC AGG TGT GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC GC M P V L L V I Y L D W D K G S G G G S G TGG GCC AAG TCG GCC AGA TCT TCT AGA GAA TTC GGC ACG AGG GTC AGG GC CTC CAC GAC W A K S A R S S R E F G T R V K D V L P Q E CCG ACT GGC CAG TCA CAG GGA AGA AGA AGG ATC TGT GGG CTG CGC TGG TGA CAT TCC P T G Q S Q A G R T CGG CGC AGG CCC GGC TGG GCG CGA AGG ACG TGT GCG GTG CGC CGG TGC CGT ATT CGG ATG CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG CGC GGT GCC CGG TGC CGT ATT CGG AGG ACG TGT CGG CGC GGC TGG TGA CAT TCC P T G Q S Q A G R T CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG CGG TGC CGG TGG CGC CGG TGC CGG TGC CGG TGC CGG TGC CGG TGC CGG TGC CGG TGG CGG C$ | | | | | | | | | | | | |
| G P S R P D L L E N S A R G * CGA CTG GCC AAT CAC AGG CAG GAA GAT GAA GGT TCT GTG GGC TGC GTT GCT GGT CAC ATT C GGC GGC GCA GGC CCG GCT GGG CGC GGA CAT GGA GGA CGT GTG CGG TGC GCC GTT GCC GTT GCG GGC GGC | | GGG | CCA | AGT | CGG | CCA | GAT | CTT | CTA | ECUNI | | |
| $\begin{array}{c} \hline & \mathbf{F} - \mathbf{tag} \\ \hline & \mathbf{F} - \mathbf{F} - \mathbf{F} \\ \hline & \mathbf{F} \\ $ | | | | | | | | | | | | |
| $\begin{array}{c} \hline & \mathbf{E} - \mathbf{tag} \\ \hline & \mathbf{E} - \mathbf{tag} \\ \hline & \mathbf{E} - \mathbf{tag} \\ \hline & \mathbf{CC} \ \mathbf{GGA} \ \mathbf{TCC} \ \mathbf{GGA} \ \mathbf{ACC} \ \mathbf{GCG} \ \mathbf{TGC} \ \mathbf{GGC} \ GGC$ | | CCD | CTC | ccc | ית ממ | CDC | n c c | CDC | C 7 7 | א מאין אין אין אין אין אין אין אין אין אין | | |
| GGC GGC GCA GGC CCG GCT GGG CGC GGA CAT GGA GGA CGT GTG CGG TGC GCC GGT GCC GT TCC GGA TCC GCT GGA ACC GCG T <u>GC GGC CGC</u> TAA TTA ATT G UH-FSE ⁺¹ : display of an artificial peptide Gene VI ATG CCA GTT CTT TTG GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC O M P V L L V I Y L D W D K G S G G G S G TGG GCC AAG TCG GCC AGA TCT TCT AGA <u>GAA TTC</u> GGC ACG AGG GCT CAT CCC CAG GAC W A K S A R S S R E F G T R V K D V L P Q E CCG ACT GGC CAA TCA CAG GCA GGA ACA TGA AGG ATC TGT GGG CTG CGT TGC TGG TCA CAT TCC P T G Q S Q A G R $ R$ CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CTT CCC CAG ATC CGC TGG AAC CGC GTG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC E-tag NotI CGC TGG AAC CGC GT <u>G</u> CGG CCG CTA ATT AAT TG stop codon | | COA | 010 | 900 | AAI | OAU | AGG | CAG | GAA | con a state and state state control barrent state and state and the state and the state and | | |
| TCC GGA TCC GCT GGA ACC GCG T <u>GC GGC CGC TAA TTA ATT G</u> UH-FSE ⁺¹ : display of an artificial peptide \longrightarrow Gene VI ATG CCA GTT CTT TTG GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC O M P V L L V I Y L D W D K G S G G G S G TGG GCC AAG TCG GCC AGA TCT TCT AGA <u>GAA TTC</u> GGC ACG AGG GTG AAG GAC GTC CTT CCC CAG GAO W A K S A R S S R E F G T R V K D V L P Q E CCG ACT GGC CAA TCA CAG GCA GGA AGA TTA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC P T G Q S Q A G R * CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATG CGC TGG AAC CGC GTG GGG CCG CTA ATT AAT TG * stop codon | | | | GGC | GGC | GCA | GGC | CCG | GCT | T GGG CGC GGA CAT GGA GGA CGT GTG CGG TGC GCC GGT GCC GTA | | |
| UH-FSE ⁺¹ : display of an artificial peptide $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | | CCA | | | | ACC | ccc | ► | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | 100 | GGA | 100 | 901 | GGA | ACC | 909 | 100 | | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | | | | | | | | | | | | |
| ATG CCA GTT CTT TTG GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC C M P V L L V I Y L D W D K G S G G G S G TGG GCC AAG TCG GCC AGA TCT TCT AGA $GAA TTC GGC$ ACG AGG $GCG GTG AAG GAC GTC CTT CCC CAG GAC W A K S A R S S R E F G T R V K D V L P Q E CCG ACT GGC CAA TCA CAG GCA GGA AGA TGA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC P T G Q S Q A G R * CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC GCG TGG AAC CGC GTG GGC CGG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC GCG TGG AAC CGC GTG CGG CGG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC GCG TGG AAC CGC GTG CGG CGG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC GCG TGG AAC CGC GTG CGG CGG CGA ATT AAT TG * stop codon$ |) | UH | -FSI | E+1: d | ispla | y of a | n arti | ficia | l pept | ptide | | |
| ATG CCA GTT CTT TTG GTT ATT TAT TTG GAT TGG GAT AAA GGA TCC GGT GGA GGC TCA GGC C M P V L L V I Y L D W D K G S G G G S G TGG GCC AAG TCG GCC AGA TCT TCT AGA $GAA TTC GGC$ ACG AGG $GCG GTG AAG GAC GTC CTT CCC CAG GAC W A K S A R S S R E F G T R V K D V L P Q E CCG ACT GGC CAA TCA CAG GCA GGA AGA TGA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC P T G Q S Q A G R * CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC GCG TGG AAC CGC GTG GGC CGG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC GCG TGG AAC CGC GTG CGG CGG CCG CTA ATT AAT TG * stop codon$ | | - | | | | | _ | Ge | ne VI | ∕I ———————————————————————————————————— | | |
| M P V L L V I Y L D W D K G S G G G S G TGG GCC AGG TCG GCC AGA TCT TCT AGA $GAA TTC$ GGC ACG AGG $GTG AAG GAC GTC CTT CCC CAG GAC W A K S A R S S R E F G T R V K D V L P Q E CCG ACT GGC CAA TCA CAG GCA GGA AGA TCA P T G Q S Q A G R * CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC CGC TGG AAC CGC GTG GCG CGG CTA ATT AAT TG * stop codon$ | | | | | | | GTT | | | | | |
| TGG GCC AAG TCG GCC AGA TCT TCT AGA <u>GAA TTC</u> <u>G</u> GC ACG AGG <u>G</u> TG AAG <u>GAC</u> <u>G</u> TC <u>C</u> TT <u>C</u> CC CAG <u>G</u> AC W A K S A R S S R E F G T R V K D V L P Q E CCG ACT <u>G</u> GC CAA TCA CAG <u>G</u> CA <u>G</u> GA AGA <u>T</u> <u>G</u> A <u>A</u> <u>G</u> G TTC T <u>G</u> T <u>G</u> <u>G</u> <u>G</u> <u>C</u> <u>G</u> <u>G</u> <u></u> <u>G</u> <u></u> | | ATG | CCA | GTT | CTT | TTG | | | | | | |
| TGG GCC AAG TCG GCC AGA TCT TCT AGA G <u>AA TTC</u> GGC ACG AGG GTG AAG GAC GTC CTT CCC CAG GAC W A K S A R S S R E F G T R V K D V L P Q E CCG ACT GGC CAA TCA CAG GCA GGA AG <mark>A TG</mark> A AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC P T G Q S Q A G R * CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC CGC TGG AAC CGC GT <u>G</u> CGG CCG CTA ATT AAT TG * stop codon | | 64355 | 17.51 | | | | 10.5% | I | | Y L D W D K G S G G S G | | |
| CCG ACT GGC CAA TCA CAG GCA GGA AGA TGA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC P T G Q S Q A G R \times CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC CGC TGG AAC CGC GTG CGG CCG CTA ATT AAT TG \times stop codon | | 64355 | 17.51 | | | | 10.5% | I | | | | |
| P T G Q S Q A G R $\overset{\times}{}$ CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC E-tag $$ NotI CGC TGG AAC CGC GT <u>G CGG CCG C</u> TA ATT AAT TG $\overset{*}{}$ stop codon | | М | Ρ | v | L | L | v | | TCT | EcoRI ApoE cDNA | | |
| P T G Q S Q A G R $\overset{\times}{}$ CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC E-tag $$ NotI CGC TGG AAC CGC GT <u>G CGG CCG C</u> TA ATT AAT TG $\overset{*}{}$ stop codon | | M TGG | P GCC | V AAG | L TCG | L GCC | V AGA | TCT | | EcoRI T AGA G <u>AA TTC</u> GGC ACG AGG GTG AAG GAC GTC CTT CCC CAG GAG | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | M TGG W | P GCC A | V AAG K | L TCG S | L GCC A | V AGA R | TCT S | S | EcoRI T AGA G <u>AA TTC</u> GGC ACG AGG GTG AAG GAC GTC CTT CCC CAG GAG R E F G T R V K D V L P Q E | | |
| CGG CGC AGG CCC GGC TGG GCG CGG ACA TGG AGG ACG TGT GCG GTG CGC CGG TGČ CGT ATC CGG ATC ———————————————————————————————————— | | M TGG W CCG | P GCC A ACT | V AAG K GGC | L TCG S CAA | L GCC A TCA | V AGA R CAG | TCT S GCA | S GGA | T AGA $GAA TTC$ GGC ACG AGG GTG AAG GAC GTC CTT CCC CAG GAG R E F G T R V K D V L P Q E A AGA TGA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC | | |
| CGC TGG AAČ CGC GT <u>G CGG CCG C</u> TA ATT AAT TG *: stop codon | | M TGG W CCG | P GCC A ACT | V AAG K GGC | L TCG S CAA | L GCC A TCA | V AGA R CAG | TCT S GCA | S GGA | ECORI T AGA G <u>AA TTC</u> GGC ACG AGG GTG AAG GAC GTC CTT CCC CAG GAG R E F G T R V K D V L P Q E A AGA TGA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC | | |
| *: stop codon | | M TGG W CCG P | P GCC A ACT T | V AAG K GGC G | L TCG S CAA Q | L GCC A TCA S | V AGA R CAG Q | TCT S GCA A | S GGA G | $\begin{array}{cccc} EcoRI & & ApoE cDNA \\ cT AGA GAA TTC GGC ACG AGG GTG AAG GAC GTC CTT CCC CAG GAG \\ R E F G T R V K D V L P Q E \\ A AGA TGA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC \\ R & & E-tag \\ \end{array}$ | | |
| | | M TGG W CCG P CGG | P GCC A ACT T CGC | V AAG K GGC G AGG Z-tag | L TCG S CAA Q CCC | L GCC A TCA S GGC | V AGA R CAG Q TGG N | TCT S GCA A GCG otI | S GGA G CGG | $\begin{array}{c} \mathbf{E} \mathbf{coRI} \\ \mathbf{cr} & \mathbf{Aga} & \mathbf{GAA} & \mathbf{TTC} & \mathbf{GGC} & \mathbf{Acg} & \mathbf{Agg} & \mathbf{Grg} & \mathbf{Aag} & \mathbf{Gac} & \mathbf{GTC} & \mathbf{CTT} & \mathbf{CCC} & \mathbf{Cag} & \mathbf{Gag} \\ \mathbf{R} & \mathbf{E} & \mathbf{F} & \mathbf{G} & \mathbf{T} & \mathbf{R} & \mathbf{V} & \mathbf{K} & \mathbf{D} & \mathbf{V} & \mathbf{L} & \mathbf{P} & \mathbf{Q} & \mathbf{E} \\ \mathbf{A} & \mathbf{AGA} & \mathbf{TGA} & \mathbf{Agg} & \mathbf{TTC} & \mathbf{TGT} & \mathbf{GGG} & \mathbf{CTG} & \mathbf{CGT} & \mathbf{TGC} & \mathbf{TGG} & \mathbf{TCA} & \mathbf{CAT} & \mathbf{TCC} & \\ \mathbf{R} & \mathbf{X} & \mathbf{TGA} & \mathbf{Agg} & \mathbf{Agg} & \mathbf{Acg} & \mathbf{TTC} & \mathbf{TGT} & \mathbf{GGG} & \mathbf{CTG} & \mathbf{CGT} & \mathbf{TGC} & \mathbf{CGG} & \mathbf{TGC} & \mathbf{CGT} & \mathbf{TCC} & \mathbf{CGG} & \mathbf{TCC} \\ \mathbf{G} & \mathbf{Aca} & \mathbf{TGG} & \mathbf{Agg} & \mathbf{Acg} & \mathbf{TGT} & \mathbf{GCG} & \mathbf{GTG} & \mathbf{CGC} & \mathbf{CGG} & \mathbf{TGC} & \mathbf{CGT} & \mathbf{ATC} & \mathbf{CGG} & \mathbf{ATC} \\ \end{array}$ | | |
| G Inst nucleotide of the ApoE cDNA in the pSP6 vector | | M TGG W CCG P CGG CGC | P GCC A ACT T CGC TGG | V AAG K GGC G AGG AGG AAC | L TCG S CAA Q CCC | L GCC A TCA S GGC | V AGA R CAG Q TGG N | TCT S GCA A GCG otI | S GGA G CGG | $\begin{array}{c} \mathbf{E} \mathbf{coRI} \\ \mathbf{cr} & \mathbf{Aga} & \mathbf{GAA} & \mathbf{TTC} & \mathbf{GGC} & \mathbf{Acg} & \mathbf{Agg} & \mathbf{Grg} & \mathbf{Aag} & \mathbf{Gac} & \mathbf{GTC} & \mathbf{CTT} & \mathbf{CCC} & \mathbf{Cag} & \mathbf{Gag} \\ \mathbf{R} & \mathbf{E} & \mathbf{F} & \mathbf{G} & \mathbf{T} & \mathbf{R} & \mathbf{V} & \mathbf{K} & \mathbf{D} & \mathbf{V} & \mathbf{L} & \mathbf{P} & \mathbf{Q} & \mathbf{E} \\ \mathbf{A} & \mathbf{AGA} & \mathbf{TGA} & \mathbf{Agg} & \mathbf{TTC} & \mathbf{TGT} & \mathbf{GGG} & \mathbf{CTG} & \mathbf{CGT} & \mathbf{TGC} & \mathbf{TGG} & \mathbf{TCA} & \mathbf{CAT} & \mathbf{TCC} & \\ \mathbf{R} & \mathbf{X} & \mathbf{TGA} & \mathbf{Agg} & \mathbf{Agg} & \mathbf{Acg} & \mathbf{TTC} & \mathbf{TGT} & \mathbf{GGG} & \mathbf{CTG} & \mathbf{CGT} & \mathbf{TGC} & \mathbf{CGG} & \mathbf{TGC} & \mathbf{CGT} & \mathbf{TCC} & \mathbf{CGG} & \mathbf{TCC} \\ \mathbf{G} & \mathbf{Aca} & \mathbf{TGG} & \mathbf{Agg} & \mathbf{Acg} & \mathbf{TGT} & \mathbf{GCG} & \mathbf{GTG} & \mathbf{CGC} & \mathbf{CGG} & \mathbf{TGC} & \mathbf{CGT} & \mathbf{ATC} & \mathbf{CGG} & \mathbf{ATC} \\ \end{array}$ | | |
| ATG start codon of the ApoE protein | | M TGG W CCG P CGG CGC | P GCC A ACT T CGC TGG op co | V AAG K GGC G AGG AGG C-tag AAC | L TCG S CAA Q CCC CGC | L GCC A TCA S GGC GT <u>G</u> | V AGA R CAG Q TGG TGG N CGG | TCT S GCA A GCG otI CCG | S GGA G CGG <u>C</u> TA | T AGA GAA TTC GGC ACG AGG GFG AAG GAC GTC CTT CCC CAG GAG R E F G T R V K D V L P Q E A AGA TGA AGG TTC TGT GGG CTG CGT TGC TGG TCA CAT TCC R * AGA TGG AGG ACG TGT GCG GTG CGC CGG TGC CGT ATC CGG ATC A ATT AAT TG | | |

2.2. Detection of Protein Display on the Surface of the Phage

To confirm expression of the ApoE polypeptide on the surface of the UH-FSE⁰ phage and verify possible frameshifting in the other 2 phages UH-FSE⁻¹ and UH-FSE⁺¹, an antibody directed against the N-terminal part of the ApoE protein was used. An empty phage, not displaying a fusion peptide, was

taken along as a negative control to determine the background value. Representative data of individual experiments are shown in Figure 4a. UH-FSE⁰ displayed a positive signal for the ApoE polypeptide confirming the display of the ApoE cDNA. Whereas UH-FSE⁻¹ did not express the ApoE polypeptide, a significant increase in ApoE expression was observed for UH-FSE⁺¹. These results indicate that in a fraction of the purified UH-FSE⁺¹ phages, the reading frame has shifted in the -1 direction resulting in the display of the ApoE polypeptide.

Figure 4. (A) Detection of ApoE expression. ApoE expression of UH-FSE⁰, UH-FSE⁻¹ and UH-FSE⁺¹ was measured via ELISA. Empty phage was used to determine background values. Experiments were performed twice independently. All samples were tested in duplicate in one ELISA. ** p < 0.001; * p < 0.01 as evaluated by one-way ANOVA followed by Tukey post-hoc test; (B) Detection of E-tag expression. E-tag expression of UH-FSE⁰, UH-FSE⁻¹ and UH-FSE⁺¹ was measured via ELISA. UH-PC was used as a positive E-tag display control whereas UH-NC was used as a negative E-tag display control. Empty phage was taken along to determine background values. Experiments have been performed 4 times independently, all samples were tested in duplicate. ** p < 0.001; * p < 0.01 except for UH-FSE⁰ vs. UH-FSE⁺¹ p < 0.05 as evaluated by one-way ANOVA followed by Tukey post-hoc test.



2.3. Detection of E-tag Expression

To confirm the results of the ApoE ELISA, expression of the E-tag, fused to the ApoE sequence, was also measured as representatively depicted in figure 4b. An empty phage was used to determine background values whereas UH-PC and UH-NC represent respectively a positive and negative control for E-tag display. A high E-tag expression was observed for both the positive control UH-PC and UH-FSE⁰ which confirmed the correct expression of the E-tag and concordant ApoE polypeptide in this reading frame. The lower E-tag expression of UH-FSE⁰ compared to the positive control can be explained by the fact that high-level expression of the ApoE polypeptide could result in some level of toxicity or growth bias to the bacterial host. This bias can be a consequence of the size (130 amino acids), the eukaryotic nature and/or possible interference of the polypeptide in the phage production process. This would in turn result in a low percentage of UH-FSE⁰ phages expressing the ApoE


polypeptide and E-tag which could also explain why the UH-FSE⁺¹ clone was selected during our selection procedure instead of UH-FSE⁰.

Although the significant increase in signal of the UH-FSE⁺¹ clone observed in the ApoE ELISA could not be confirmed with the E-tag antibody, a higher E-tag signal was observed for the UH-FSE⁺¹ clone compared to the UH-FSE⁻¹ clone. E-tag expression of UH-NC and UH-FSE⁻¹ again equaled background values confirming that no E-tag is displayed at the surface of these phages.

2.4. Specific Enrichment of Frameshifted Phage Clone UH-FS

If the original enrichment of UH-FS during the selection rounds on MS plasma would be the result of specific interactions between the frameshifted ApoE polypeptide and plasma antibodies, antibodies towards this ApoE polypeptide should be present in the plasma used for the selection rounds [10]. For that reason, an ELISA was performed where reactivity towards UH-FSE⁰, UH-FSE⁻¹, UH-FSE⁺¹ and empty phage was analyzed in the plasma of the 10 MS patients used for the selection rounds. Figure 5 clearly shows an increased antibody reactivity towards UH-FSE⁰ compared to UH-FSE⁻¹ and UH-FSE⁺¹ indicating that ApoE-specific antibodies are indeed present in the plasma of these MS patients resulting in the enrichment of UH-FS during the selection procedure.

Figure 5. Detection of ApoE-immunoreactivity in the plasma of MS patients. Immunoreactivity towards the different UH-FSE phages was measured in the individual plasma of 10 MS patients that were used for the selection rounds. UH-FSE⁰ displays the ApoE protein in the correct reading frame. UH-FSE⁻¹ and UH-FSE⁺¹ represent respectively a -1 and +1 shift in the reading frame of ApoE. Background values were determined by measuring reactivity towards an empty phage not displaying any protein. Results are given as a ratio of the OD_{450nm} specific phage/OD_{450nm} empty phage.



By cloning an E-tag in frame with the ApoE cDNA, we were able to monitor the display of the cDNA at the surface of the phage. This was achieved either by an antibody directed to the polypeptide itself or directed to the E-tag fused to the polypeptide. Our results clearly indicate that for this cDNA fragment, frameshifting occurs in a proportion of the phages resulting in the expression of the ApoE polypeptide and attached E-tag in the +1 reading frame. In addition, an increased immunoreactivity

towards the ApoE polypeptide could be observed in the plasma of MS patients that was used for the selection of UH-FS, which indicates that enrichment of UH-FS was the result of specific interactions between the frameshifted ApoE polypeptide displayed on the phage and plasma antibodies.

The phenomenon of frameshifting has implications for affinity selection procedures applied on complex cDNA libraries since frameshift mutations can revert display phenotypes on phage in the presence of a suitable selection pressure. As a result, a single phage clone could encode different antigenic targets. Although this can benefit the complexity of the library, deducing the correct peptide sequence that has been selected by the selector molecule can be difficult, implying the need to verify the selection specificity in a phage-free format (*i.e.* purified peptides or recombinant proteins).

3. Experimental

3.1. Serological Antigen Selection of a Multiple Sclerosis cDNA Phage Display Library on Patient Plasma

Serological antigen selection (SAS) was applied on a MS cDNA phage display library as described previously [10]. A cDNA phage clone UH-FS (short for University Hasselt-frameshifting) was selected multiple times after affinity selecting an MS cDNA phage display library against MS plasma and was chosen for analysis of frameshifting. The cDNA of UH-FS was identical to the nucleotide sequence of the ApoE sequence (from nucleotide position –50 to 389). However, after translation of the nucleotide sequence an early stop codon was observed due to out of frame insertion of the cDNA in the pSP6 phagemid vector which prevented the display of the protein.

3.2. Generation of E-tag Constructs

An overview of the study is represented in Figure 2. An ApoE - E-tag construct was generated by C-terminal fusion of an E-tag (GAPVPYPDPLEPR) and NotI restriction site to the ApoE sequence of UH-FS using the ApoE forward and E-tag reverse primer (see Figure 2A and Table S1 for primer sequences in the appendix). A negative control (NC) for E-tag display was generated by an out of frame fusion of the E-tag to the 3'-end of gVI (Figure 2B), resulting in a stop codon preventing the display of the E-tag. This was done using the overlapping ApoE forward and the NC reverse primer. A positive control (PC) for E-tag display was generated by using the overlapping ApoE forward and PC reverse primer. Addition of an extra nucleotide to the PC reverse primer resulted in an in frame fusion of the E-tag at the 3'-end of gVI. All primers were obtained from Eurogentec (Seraing). PCR products were purified using the GFX gel band purification kit (GE Healthcare), ligated into the pCR2.1 TOPO vector and transformed into Escherichia coli (E. coli) Top10 cells according to manufacturer's instructions (TopoTA cloning kit, Invitrogen; Figure 2C). Insert sequences were confirmed using M13 forward and reverse primer. After BglII and NotI digestion, the ApoE – E-tag and the E-tag control constructs were ligated into the pSP6 vectors digested with the same restriction enzymes (Figure 2D). Ligation mixtures were used to transform E. coli TG1 cells by electroporation to obtain UH-FSE⁰ (correct reading frame of the ApoE gene), UH-FSE⁻¹ (-1 shift in the reading frame of the ApoE gene), UH-FSE⁺¹ (+1 shift in the reading frame of the ApoE gene), UH-PC (positive E-tag display control) and UH-NC (negative E-tag display control) as depicted in Figure 2D. Resulting colonies were picked and sequence was confirmed with gVI forward primer. Phage were purified as described previously [17].

Purified phage clones were used in ELISA to analyse immunoreactivity towards the displayed ApoE protein on the one hand and the level of E-tag expression on the other hand (Figure 2F).

3.3. Detection of ApoE and E-tag Expression by ELISA

ApoE and E-tag expression of purified phage clones UH-FSE⁺¹, UH-FSE⁰, UH-FSE⁻¹, UH-PC and UH-NC was measured by ELISA as shown in Figure 2F. Empty phage not displaying a peptide was taken along as a negative control to set the background value. The cutoff for a positive signal was set at 1.5 times the background value. Briefly, 96-well flat-bottomed microtiter plates (Falcon/BD) were coated overnight at 4 °C with 200 µL anti-ApoE antibody (LifeSpan BioSciences) or anti-E-tag antibody (GE Healthcare), 10 µg/mL in coating buffer (0.1 M sodium hydrogen carbonate pH 9.6) and blocked with 200 µL of 2% MPBS (2% (w/v) skimmed milk powder in PBS, 750 mM NaCl, 40 mM Na₂HPO₄, 7.8 mM KH₂PO₄, pH 7.4) for 1 h at room temperature (RT). PEG (20% polyethylene glycol - 2.5 M NaCl) - purified phage (10¹⁰ phage/well) were preblocked with 2% MPBS in a 96-well roundbottomed plate (Nunc) for 1h at 37 °C, followed by 30 min shaking at RT. After washing with 0.1% (v/v) PBS/Tween 20 (PBST) and PBS, the preblocked phage were transferred to the antibody-coated plate and incubated for 1h at 37 °C and 30 min shaking at RT. After washing the plate with 0.1% PBST and PBS, 150 µL of a peroxidase conjugated anti-M13 monoclonal antibody (Amersham/Pharmacia/Biotech), diluted 1:5,000 in 2% MPBS was incubated for 1h shaking at RT. After washing the plate with 0.1% PBST and PBS, 130 µL of a 3,3',5,5' tetramethylbenzidine dihydrochloride solution (10 mg/mL) was added. Colour development was chromogen stopped with 65 µL/well 2 M H₂SO₄. The plates were read at 450 nm in a Bio-Rad Benchmark microplate reader (Bio-Rad). ApoE experiments were performed twice independently whereas experiments with the anti-Etag antibody were performed four times independently. All samples were tested in duplicate in one ELISA. Statistical analysis was performed by one-way ANOVA followed by Tukey post-hoc test.

3.4. Measuring ApoE-antibody reactivity in plasma of MS patients

Antibody reactivity towards the ApoE polypeptide was measured in the plasma of 10 MS patients used for the selection of UH-FS. Reactivity towards UH-FSE⁺¹, UH-FSE⁰, UH-FSE⁻¹ was measured as described previously [7].

4. Conclusions

In this study we analyzed the occurrence of frameshifting in the p6 phage display system. By cloning a cDNA sequence in 3 different reading frames in a pSP6 phagemid vector, we were able to demonstrate the translation of the corresponding cDNA not only in the correct reading frame but also in the +1 reading frame. These results indicate that part of the phages was subjected to frameshifting leading to the in-frame expression of the ApoE polypeptide. Our results indicate that translational events like frameshifting also occur in the p6 phage display system emphasizing the need to confirm ligand-target binding properties in a phage-free assay using synthetic peptides or recombinant proteins.

Acknowledgements

This work was supported by a grant from the Bijzonder Onderzoeksfonds Limburg (BOF) of Hasselt University and by the transnational University Limburg (tUL). K.S. and V.S are supported by a grant from Research Foundation Flanders. The authors would like to thank Prof. Johan Robben for helpful discussion and Igna Rutten for technical assistance.

References

- 1. Smith, G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science* **1985**, *228*, 1315-1317.
- 2. Parmley, S.F.; Smith, G.P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. *Gene* **1988**, *73*, 305-318.
- 3. Smith, G.P.; Petrenko, V.A. Phage Display. Chem. Rev. 1997, 97, 391-410.
- 4. Jacobsson, K.; Rosander, A.; Bjerketorp, J.; Frykberg, L. Shotgun phage display selection for bacterial receptins or other exported proteins. *Biol. Proced. Online* **2003**, *5*, 123-135.
- Jespers, L.S.; Messens, J.H.; De Keyser, A.; Eeckhout, D.; Van, d.B., I; Gansemans, Y.G.; Lauwereys, M.J.; Vlasuk, G.P.; Stanssens, P.E. Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI. *Biotechnology (NY)* 1995, *13*, 378-382.
- 6. Hufton, S.E.; Moerkerk, P.T.; Meulemans, E.V.; de Bruine, A.; Arends, J.W.; Hoogenboom, H. R. Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands. *J. Immunol. Methods* **1999**, *231*, 39-51.
- 7. Somers, V.; Govarts, C.; Hellings, N.; Hupperts, R.; Stinissen, P. Profiling the autoantibody repertoire by serological antigen selection. *J. Autoimmun.* **2005**, *25*, 223-228.
- 8. Somers, V.; Govarts, C.; Somers, K.; Hupperts, R.; Medaer, R.; Stinissen, P. Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. *J. Immunol.* **2008**, *180*, 3957-3963.
- Somers, V.A.; Brandwijk, R.J.; Joosten, B.; Moerkerk, P.T.; Arends, J.W.; Menheere, P.; Pieterse, W.O.; Claessen, A.; Scheper, R.J.; Hoogenboom, H.R.; Hufton, S.E. A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. *J. Immunol.* 2002, *169*, 2772-2780.
- 10. Govarts, C.; Somers, K.; Hupperts, R.; Stinissen, P.; Somers, V. Exploring cDNA phage display for autoantibody profiling in the serum of multiple sclerosis patients: optimization of the selection procedure. *Ann. NY Acad. Sci.* **2007**, *1109*, 372-384.
- Somers, K.; Stinissen, P.; Somers, V. Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis. *Ann. NY Acad. Sci.* 2009, *1173*, 92-102.
- 12. Jacobsson, K.; Frykberg, L. Cloning of ligand-binding domains of bacterial receptors by phage display. *Biotechniques* **1995**, *18*, 878-885.
- 13. Jacobsson, K.; Frykberg, L. Phage display shot-gun cloning of ligand-binding domains of prokaryotic receptors approaches 100% correct clones. *Biotechniques* **1996**, *20*, 1070-1071.

- Carcamo, J.; Ravera, M.W.; Brissette, R.; Dedova, O.; Beasley, J.R.; Alam-Moghe, A.; Wan, C.; Blume, A.; Mandecki, W. Unexpected frameshifts from gene to expressed protein in a phagedisplayed peptide library. *Proc. Natl. Acad. Sci. USA* 1998, 95, 11146-11151.
- 15. Goldman, E.; Korus, M.; Mandecki, W. Efficiencies of translation in three reading frames of unusual non-ORF sequences isolated from phage display. *FASEB J.* **2000**, *14*, 603-611.
- 16. Suzuki, Y.; Ito, S.; Otsuka, K.; Iwasawa, E.; Nakajima, M.;Yamaguchi, I. Preparation of functional single-chain antibodies against bioactive gibberellins by utilizing randomly mutagenized phage-display libraries. *Biosci. Biotechnol. Biochem.* **2005**, *69*, 610-619.
- Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, G. Bypassing immunization. Human antibodies from V-gene libraries displayed on phage. *J. Mol. Biol.* 1991, 222, 581-597.

Appendix

| Table S1. Primers used in the study. | | | | | | |
|--------------------------------------|--|--|--|--|--|--|
| Name | Sequence | | | | | |
| ApoE forward primer | GGATCCGGTGGAGGCTCAGGCGGAGGGCCAAGTCGG | | | | | |
| Apol: forward printer | CCAGATCTTCTAGAGAATTC | | | | | |
| E-tag reverse primer | GCGGCCGCACGCGGTTCCAGCGGATCCGGATACGGC | | | | | |
| E-tag reverse primer | ACCGGCGCACCGCACACGTCCTCCAT | | | | | |
| NC reverse primer | GCGGCCGCACGCGGTTCCAGCGGATCCGGATACGGC | | | | | |
| Ne reverse primer | <u>ACCGGCGCACC</u> CCTCGTGCC GAATT | | | | | |
| PC reverse primer | GCGGCCGCACGCGGTTCCAGCGGATCCGGATACGGC | | | | | |
| i e reverse primer | <u>ACCGGCGCACC</u> ACCTCGTGCC GAATT | | | | | |
| M13 forward primer | CAGGAAACAGCTATGAC | | | | | |
| M13 reverse primer | GTAAAACGACGGCCAG | | | | | |
| gVI forward primer | TTACCCTCTGACTTTGTTCAGG | | | | | |

Table S1. Primers used in the study.

All primers are listed from 5' to 3'. Overlapping nucleotides are indicated in bold. The underlined bases represent the E-tag sequence while italic text represents *Not*I restriction site.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).